Indonesia Medical Product Registration Guide for 2026

Indonesia uses different registration routes for different medical products. For foreign manufacturers, medical device registration in Indonesia falls under the Ministry of Health, while medicinal drug registration falls under BPOM. Mixing those routes can waste months before the technical review even starts.

This 2026 guide focuses on the issues foreign manufacturers and market-entry teams need to settle before filing: the correct authority, Indonesian license holder, device risk class, dossier, current review timetable, renewal planning, postmarket duties, and the approaching halal requirement for certain products.

Which Authority Regulates Your Medical Product in Indonesia?

Start with product classification, not paperwork. Indonesia does not use one regulator or one dossier route for every product sold into the healthcare market.

The distinction matters because the Ministry of Health and BPOM use different applicant criteria, evidence requirements, systems, and evaluation rules. A device dossier should not be planned around a BPOM drug-registration workflow.

What Changed for Medical Device Registration in 2026?

The legal basis changed. Ministry of Health Regulation No. 5 of 2026 on Health Supplies took effect on 4 May 2026 and revoked Ministry of Health Regulation No. 62 of 2017, the rule many older medical-device guides still cite.

For risk-based business licensing and product-service standards, Ministry of Health Regulation No. 11 of 2025 remains a central current reference. It covers the licensing standards used for medical-device distribution and Izin Edar applications, including imported devices.

That means a 2026 registration plan should be checked against the current rules rather than copied from a pre-2026 checklist. Old assumptions about timelines, distributor certification, renewal, or submission routes may no longer match the controlling framework.

Medical Device Registration in Indonesia: Current Filing Path

Confirm the Product and Risk Class

Indonesia classifies medical devices into four risk classes. Class A covers low-risk devices, Class B covers low to moderate risk, Class C covers moderate to high risk, and Class D covers high-risk devices.

The class affects the review timetable and the depth of technical evidence. Do not classify a product from its trade name alone. Intended use, technology, contact, invasiveness, and other product characteristics can affect the result.

Confirm the Indonesian Distributor and CDB Readiness

An overseas manufacturer needs an eligible Indonesian filing party for an imported-device application. Under the current service standard, the applicant documentation includes the business license for a medical-device distributor and the business supporting license for a good distribution practice certificate, commonly referred to as CDB.

The manufacturer also needs an appointment document that identifies the Indonesian distributor and product scope. Treat that appointment as part of regulatory control, not a sales formality.

If your market-entry plan includes establishing your own Indonesian company, review the PT PMA registration process before assuming the new entity can hold every healthcare license you need. The company setup, KBLI selection, distributor licensing, and product-registration workstreams need to fit together.

For the wider licensing context after company formation, see the guide to industry-specific licenses after PT PMA registration.

Build the Import Dossier

The current imported-device standard calls for administrative and technical evidence that supports the manufacturer, product identity, safety, performance, and market authorization history.

Typical required document categories include the manufacturer appointment, quality management documentation, a valid marketing authorization from the country of origin or a Certificate of Free Sale where applicable, a declaration of conformity, and technical product information.

The technical file may also need material information, production details, packaging, verification and validation records, performance evidence, risk documentation, sterility evidence where relevant, labeling, instructions for use, and postmarket procedures. The exact set depends on the device.

Submit Through the OSS Integrated Licensing Flow

Ministry of Health Regulation No. 11 of 2025 places the licensing process within Indonesia’s risk-based OSS framework. The Ministry of Health also operates Regalkes as its official medical-device and PKRT registration application environment.

Make sure the company data, distributor license, appointment documents, product identity, and dossier use the same names and model references before submission. Small identity mismatches can trigger avoidable clarification requests.

Respond to Evaluation and Verify the Authorization

The current service standard allows up to two correction rounds during evaluation. The applicant receives a limited correction window, so the team responsible for technical answers should be available while the application is under review.

After issuance, use the Ministry of Health’s Info Alkes and PKRT platform to verify the public registration record and Izin Edar information. That platform is the official public source for registered medical devices, PKRT products, industry data, and distributor information.

Medical Device Registration Timeline in Indonesia

For new imported-device applications, Ministry of Health Regulation No. 11 of 2025 lists the following maximum service times. The regulation defines these as working days.

The same service standard lists 13 working days for renewal, 16 working days for a change, 16 working days for a combined renewal and change, and 12 working days for the notification route.

Do not use those figures as the total market-entry calendar. Dossier preparation, distributor licensing readiness, document legalization, product testing where required, correction rounds, and internal response time can extend the project.

Medical Device Registration Cost in Indonesia

There is no responsible way to budget the project from an old online fee table. Government filing charges and applicable PNBP should be checked against the current official tariff and the filing system at the time of application.

Your total budget may also include distributor licensing and CDB readiness, dossier localization, legalization or Apostille work, testing where required, label and instructions-for-use adaptation, regulatory support, and postmarket maintenance.

For a scoped assessment of the licensing work around a specific product and Indonesian entity, review InvestinAsia’s licenses and permits support.

Why the Distributor Appointment Affects License Control

Foreign manufacturers often treat distributor selection as a commercial decision. For imported medical devices, it also affects the regulatory file because the appointment document and the Indonesian distributor’s licensing sit inside the application.

This becomes important when the commercial relationship changes. What teams sometimes call an Indonesia medical device license transfer should be planned as a regulated agency transition, with the new filing and stock position handled under the Ministry of Health rules.

The current imported-device standard allows the previous distributor to finish distributing remaining stock for up to six months after the new authorization is issued, subject to Ministry of Health approval. That transition window should be written into your operational plan rather than handled after the relationship ends.

Before signing an appointment, check the product and model scope, appointment term, renewal cooperation, variation responsibilities, access to technical documents, and exit support. Those points affect both launch and the ability to maintain the authorization later.

Postmarket and Renewal Obligations After Approval

Izin Edar is not the end of the compliance work. The current Ministry of Health standard requires postmarket reporting for imported medical devices, including distribution reporting, adverse-event reporting, and reporting of risks that could affect product availability.

The standard also requires a KFA code for each Izin Edar. Build the KFA work and postmarket reporting ownership into the launch checklist so the regulatory team does not hand an incomplete file to commercial operations.

For imported devices, the renewal application must be submitted no later than nine months before the Izin Edar expires. A renewal file also depends on current licensing and appointment documents, so contract dates and license expiry dates should sit on the same compliance calendar.

Treat Halal Compliance as a Separate 2026 Workstream

BPJPH states that the next staged halal certification obligation begins on 18 October 2026 for several product categories, including Class A medical devices. The agency also states that the stage extends to covered imported products.

Do not treat the Kemenkes Izin Edar as a substitute for halal compliance. Check whether the product falls within the relevant halal category, then confirm the material and product-specific requirements under the halal rules that apply to it.

How to Check a Medical Device Registration in Indonesia

If you are researching the Indonesia medical device registration database, start with Info Alkes and PKRT. The Ministry of Health describes it as its official public platform for registered medical devices and PKRT products, distributor information, and Izin Edar monitoring.

Use the public record as a due-diligence check on the Indonesian license holder and product authorization. For a foreign manufacturer, this is useful before appointing a distributor, during launch preparation, and when checking whether a renewal or agency change appears correctly in the public record.

Drug Registration Uses a Separate BPOM Track

Medicinal drugs do not use the Class A to D device pathway above. BPOM regulates drug registration under its drug-registration framework, including BPOM Regulation No. 23 of 2025, the fifth amendment to the 2017 drug-registration rule.

BPOM also operates the official Drug Registration portal and NEW-AERO environment. Drug applicant criteria, dossier content, evaluation tracks, variations, import controls, and renewal rules should therefore be planned under the current BPOM framework rather than copied from a medical-device checklist.

This separation also limits keyword and operational confusion: a medical product may sit in Indonesia’s healthcare sector, but the regulator depends on what the product actually is and how it is intended to be used.

A Practical Market Entry Sequence for Foreign Manufacturers

1. Classify the product first. Confirm whether it is a medical device, in vitro diagnostic device, PKRT product, drug, supplement, or another regulated category.
2. Identify the correct regulator and approval. Use the Ministry of Health route for medical devices and PKRT, and the relevant BPOM route for products under BPOM supervision.
3. Choose the Indonesian filing structure. Decide whether to work through an eligible local distributor or establish an Indonesian entity that can obtain the licenses required for the intended activity.
4. Align the commercial appointment with the dossier. Product names, models, manufacturer identity, appointment scope, CFS data, labeling, and technical records should tell the same story.
5. File with a response team ready. Assign owners for regulatory questions, technical evidence, legalized documents, and corrections before the reviewer asks for them.
6. Build the lifecycle calendar before launch. Track postmarket reporting, KFA, renewal, agency term, license validity, and any separate halal obligation that applies to the product.

Common Errors That Create Rework

• Using the wrong regulator. Medical devices belong to the Ministry of Health route, while medicinal drugs use BPOM.
• Building a 2026 filing around revoked guidance. Permenkes 62/2017 was revoked when Permenkes 5/2026 took effect.
• Preparing the dossier before confirming the filing entity. Distributor licensing, CDB status, and manufacturer appointment affect the imported-device file.
• Letting product identifiers drift. Model names, intended use, manufacturer details, labels, and supporting certificates need consistent data.
• Treating service-standard days as the entire project timeline. Preparation and correction work sit outside a simple review-day estimate.
• Leaving lifecycle compliance until after launch. Renewal, postmarket reporting, KFA, agency terms, and applicable halal obligations need owners and dates.

For foreign manufacturers, the strongest registration plan connects the product classification, Indonesian license holder, dossier, launch schedule, and postmarket responsibilities from the start. That gives management a more realistic launch date and reduces the chance that a commercial decision creates a regulatory reset.